L-Ornithine L-Aspartate

Description

L-Ornithine L-Aspartate is used for protecting the liver from harmful chemicals or free radicals. It is also used to treat or relieve certain specific symptoms associated with liver diseases.

Side effects

Major & minor side effects for L-Ornithine L-Aspartate

  • Nausea and Vomiting
  • Diarrhea
  • Flatulence
  • Stomach pain
  • Pain in the limbs
  • Allergic skin reaction

Uses of L-Ornithine L-Aspartate

What is it prescribed for?

  • Liver disease
Read More
Concerns

Commonly asked questions

  • Onset of action
    The amount of time required for this medicine to show its action is not clinically established.
  • Duration of effect
    The amount of time for which this medicine remains active in the body is not clinically established.
  • Safe with alcohol?
    Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
  • Is it habit forming?
    No habit-forming tendencies were reported.
  • Usage in pregnancy?
    This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before receiving/taking this medicine.
  • Usage while breast-feeding?
    This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving/taking this medicine.

Allergy

This medicine is not recommended for use in patients with a known allergy to L-Ornithine L-Aspartate or any other inactive ingredients present along with it.

Severe kidney impairment

This medicine is not recommended for use in patients with severe kidney diseases due to the increased risk of worsening of the patient’s condition.
Warnings for special population

Pregnancy

This medicine is not recommended for use in pregnant women unless necessary. All the risks and benefits should be discussed with the doctor before receiving/taking this medicine.

Breast-feeding

This medicine is not recommended for use in breastfeeding women unless absolutely necessary. All the risks and benefits should be discussed with the doctor before receiving/taking this medicine.
General warnings

Clinical monitoring

Regular monitoring of serum and urinary levels of urea is necessary while receiving the parenteral (injection/infusion) form of this medicine. Your dose may be adjusted by your physician based on these parameters to avoid undesired side effects.

Dental caries

Prolonged use of this medicine may cause harmful effects on the teeth such as caries. Report any unusual symptoms to the doctor on priority. Appropriate dose adjustments or replacement with a suitable alternative may be required in some cases based on the clinical condition.

Allergic to excipients

The oral forms of this medicine are normally formulated with Fructose as an excipient. Hence, patients with diabetes mellitus and fructose intolerance should not consume the oral forms of this medicine.

Use in children

This medicine is not recommended for use in children since the safety and efficacy of use are not clinically established.

Missed Dose

Infusion/Injection: Since this medicine is usually administered by a qualified healthcare professional in the clinical/hospital setting, the likelihood of a missed dose is very low. Oral form: Take the missed dose as soon as you remember. If it is almost time for your next dose, skip the missed dose. Do not double your dose to make up for the missed one.

Overdose

Infusion/Injection: Since this medicine is administered in the hospital or clinical setting by a qualified healthcare professional, the likelihood of an overdose is very low. However, emergency medical treatment will be initiated by the doctor if an overdose is suspected. Oral form: Seek emergency medical treatment or contact the doctor in case of an overdose.
All drugs interact differently for person to person. You should check all the possible interactions with your doctor before starting any medicine.
Interaction with Alcohol

Description

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.

Instructions

Interaction with alcohol is unknown. It is advisable to consult your doctor before consumption.
Interaction with Medicine
Disease interactions

Disease

Information not available.
Food interactions
Information not available.
Lab interactions
Information not available.
Infusion/Injection: This medicine is usually administered in the clinical/hospital setting under the supervision of a qualified healthcare professional. Follow all the instructions given by your doctor. Inform the doctor if you have a known allergy to this medicine. Report all your current medicines as well as your medical conditions to the doctor before receiving this medicine. Oral form: Take this medicine with or without food. Do not take in larger or smaller amounts than advised/prescribed. Consult the doctor if you experience any undesired side effects. Ensure that the course of treatment is completed. Do not stop the use of this medicine without consulting your doctor.
Miscelleneous

Can be taken with or without food, as advised by your doctor

To be taken as instructed by doctor

Does not cause sleepiness

How it works
This medicine works by facilitating the process of detoxification and regeneration of liver cells affected by liver diseases caused due to various factors.
Legal Status

Approved

Unknown

Unknown

Approved

Classification

Category

Hepatoprotective Agent

Schedule

Schedule H

[Internet]. Meppo.com. 2018 [cited 6 August 2018]. Available from:

http://www.meppo.com/pdf/drugs/874-HEPA-MERZ-1331899928.pdf

[Internet]. Beximcopharma.com. 2018 [cited 6 August 2018]. Available from:

https://beximcopharma.com/images/stories/product-pdf/Hepagurd.pdf

L-Ornithine L-aspartate [Internet]. Pubchem.ncbi.nlm.nih.gov. 2018 [cited 6 August 2018]. Available from:

https://pubchem.ncbi.nlm.nih.gov/compound/L-Ornithine_L-aspartate_salt#section=Top

Sikorska H e. [Physiological functions of L-ornithine and L-aspartate in the body and the efficacy of administration of L-ornithine-L-aspartate in conditions of ... - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 6 August 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/20642112

Stauch S e. Oral L-ornithine-L-aspartate therapy of chronic hepatic encephalopathy: results of a placebo-controlled double-blind study. - PubMed - NCBI [Internet]. Ncbi.nlm.nih.gov. 2018 [cited 6 August 2018]. Available from:

https://www.ncbi.nlm.nih.gov/pubmed/9625322

How will this medicine affect me?

Consult top doctors online and get an answer now
Consult now
Consult now

Looking for a doctor?

Book an appointment with the top doctors near you
Book now
Book now
Something doesn’t feel right?
Report an error

Information on this page was last updated on 14 Dec 2018

Disclaimer

We’ve made all possible efforts to ensure that the information provided here is accurate, up-to-date and complete, however, it should not be treated as a substitute for professional medical advice, diagnosis or treatment. Practo only provides reference source for common information on medicines and does not guarantee its accuracy or exhaustiveness. The absence of a warning for any drug or combination thereof, should not be assumed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Practo does not assume any responsibility for any aspect of healthcare administered with the aid of information provided above. If you have any doubts about your medication then we strongly recommend that you consult with your doctor, nurse or healthcare provider. See detailed T&C here.